Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

The two drugs are Novo Nordisk's top growth drivers, and together comprise over 60% of its total revenue. However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 3.6% on Friday after the U.S. Department of Health and Human ...

See the 10 stocks » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...